A Phase 1, randomized, placebo-controlled study of oral GS-6207 in HIV-negative individuals
Latest Information Update: 17 Mar 2020
At a glance
- Drugs Lenacapavir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
Most Recent Events
- 17 Mar 2020 New trial record
- 11 Mar 2020 Interim results presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 11 Mar 2020 Interim Results published in the Gilead Sciences Media Release.